ARS Pharmaceuticals Inc Investigated By The Schall Law Firm And Impacted Investors Urged To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate Dialogues
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc And Urges Affected Investors To Start Conversations
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc Is Under Examination By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Affected Investors To Start Conversation, ARS Pharmaceuticals Inc Is Under Scrutiny
LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Probe Into ARS Pharmaceuticals Inc And Urges Affected Investors To Start Conversation
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investigation Into ARS Pharmaceuticals Inc Initiated By The Schall Law Firm Encouraging Impacted Investors To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Urging Affected Investors To Initiate Conversation
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Inquiry Into ARS Pharmaceuticals Inc And Encourages Impacted Investors To Start Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Starts Investigation Into ARS Pharmaceuticals Inc And Urges Affected Investors To Begin Interaction
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
